

# Predictors of mortality in solid-organ transplant recipients with infections caused by *Acinetobacter baumannii*

Hua Liu<sup>1</sup>  
Qifa Ye<sup>2,3</sup>  
Qiquan Wan<sup>2</sup>  
Jiandang Zhou<sup>4</sup>

<sup>1</sup>Central Sterile Supply Department, <sup>2</sup>Department of Transplant Surgery, Third Xiangya Hospital, Central South University, Changsha, <sup>3</sup>Department of Transplant Surgery, Zhongnan Hospital, Wuhan University, Wuhan, <sup>4</sup>Department of Clinical Laboratory of Microbiology, Third Xiangya Hospital, Central South University, Changsha, People's Republic of China

**Abstract:** *Acinetobacter baumannii* can cause a serious infection in solid-organ transplant (SOT) recipients, and more data on *A. baumannii* infection is needed. We sought to investigate the epidemiology and distribution of *A. baumannii* isolates in SOT recipients. We also investigated the risk factors for overall in-hospital mortality and infection-related 30-day mortality using multivariate logistic regression analysis. A double-center retrospective study of SOT recipients who were infected with *A. baumannii* between January 2003 and January 2015 was conducted. A total of 71 individuals developed 93 episodes of *A. baumannii* infection, with a mean age of 44.5 years (44.5±11.9 years). Ninety percent of recipients had nosocomial origin *A. baumannii* infection, with the bloodstream as the most common site of infection (32.4%). Septic shock developed in 23.9% (17 of 71) of all recipients with *A. baumannii* infection. Morbidity and mortality rates of *A. baumannii* infections were high in SOT recipients. The incidence rate of *A. baumannii* infection in SOT recipients was 3.9% (71 of 1,821). Overall in-hospital mortality and infection-related 30-day mortality were 53.5% (38 of 71) and 40.8% (29 of 71), respectively. Risk factors independently associated with overall in-hospital mortality were mechanical ventilation at onset of *A. baumannii* infection (odds ratio [OR] 6.29, 95% confidence interval [CI] 1.48–26.85;  $P=0.013$ ), liver or liver–kidney transplantation (OR 15.33, 95% CI 1.82–129.18;  $P=0.012$ ), and late-onset *A. baumannii* infection (OR 7.61, 95% CI 1.07–54.36;  $P=0.043$ ). A platelet count  $<50,000/\text{mm}^3$  (OR 12.76, 95% CI 1.28–126.81;  $P=0.030$ ) and mechanical ventilation at onset of *A. baumannii* infection (OR 189.98, 95% CI 13.23–2,728.81;  $P<0.001$ ) were identified as independent risk factors for infection-related 30-day mortality. In conclusion, the morbidity and mortality rates of *A. baumannii* infections were high in SOT recipients. Mechanical ventilation at onset of *A. baumannii* infection was associated with higher overall in-hospital mortality and infection-related mortality. For overall in-hospital mortality, liver or liver–kidney transplantation and late-onset *A. baumannii* infection, and for infection-related mortality, thrombocytopenia were also risk factors, respectively.

**Keywords:** *A. baumannii*, infection, predictors, mortality, solid-organ transplantation

## Background

Bacteria can cause serious infection after solid-organ transplantation (SOT), with significant morbidity and mortality rates.<sup>1–4</sup> The overall infection rate of *Acinetobacter baumannii* infection among SOT recipients is 1.4%–6.1%, and the mortality rate ranges from 39% to 80%.<sup>5–10</sup>

*A. baumannii* is a non-lactose-fermenting Gram-negative bacilli widely distributed in nature. It is an increasingly resilient opportunistic pathogen in critically ill or immunocompromised patients, associated with soft-tissue infection, catheter-associated bacteremia, ventilator-associated pneumonia, urinary tract infection, and peritonitis.<sup>11–13</sup>

Correspondence: Qiquan Wan  
Department of Transplant Surgery,  
Third Xiangya Hospital, Central  
South University, 138 Tongzipo Road,  
Changsha, Hunan 410013, People's  
Republic of China  
Tel +86 731 8861 8312  
Fax +86 731 8861 8312  
Email 13548685542@163.com

*A. baumannii* is particularly problematic, due to its capacity of persisting in the hospital environment, including among health care workers, resulting in clonal outbreaks.<sup>14–17</sup>

Although SOT recipients are particularly susceptible to *A. baumannii* infection with high morbidity and mortality, little has been published regarding the impact and features of *A. baumannii* infections.<sup>5,6,8,12,18</sup> Herein, in the largest sample-size cohort study specifically focusing on *A. baumannii* infections in SOT recipients so far, our objective was to determine the epidemiology and risk factors for mortality.

## Materials and methods

### Ethics statement

The study protocol was approved by the Third Xiangya Hospital, Central South University and the Zhongnan Hospital, Wuhan University Medical Ethical Committee prior to patient identification and data collection.

### Study population

This study was conducted at both the Third Xiangya Hospital, an 1,800-bed teaching hospital, affiliated with Central South University, Changsha, People's Republic of China (PRC), with an active abdominal SOT program (annual average of 30 liver and 150 kidney transplants) and Zhongnan Hospital, a 1,200-bed teaching hospital, affiliated with Wuhan University, Wuhan, PRC, with an active abdominal SOT program (annual average of 40 liver and 100 kidney transplants). The medical records of SOT recipients with symptomatic *A. baumannii* infection occurring between January 1, 2003 and January 1, 2015 at both hospitals were retrospectively reviewed. Maintenance immunosuppression was based on calcineurin inhibitors (cyclosporine or tacrolimus) and corticosteroids, with or without mycophenolate mofetil/azathioprine.

### Study design and data collection

We performed a retrospective study to investigate the epidemiology of pathogens and risk factors for overall in-hospital mortality and infection-related 30-day mortality in SOT recipients with *A. baumannii* infection. Demographic and clinical characteristics included age, sex, induction immunosuppressives, body temperature at the onset of infection, site and date of diagnosis of *A. baumannii* infection, nosocomial origin of infection, empirical antimicrobial therapy, acute rejection, reoperation, multidrug-resistant (MDR) *A. baumannii*, intensive care unit (ICU) stay, mechanical ventilation, and septic shock, and the laboratory records of these recipients were analyzed. The laboratory variables

were collected within the first 24 hours after the culture was drawn, including serum creatinine and albumin levels and white blood cell, platelet, and lymphocyte counts. All episodes of *A. baumannii* infection were reviewed, and only the first episode was included for further statistical analyses. The follow-up time of all recipients was at least 1 month after the onset of *A. baumannii* infection.

### Definitions

The presence of infection, including bacteremia, pneumonia, peritonitis, pleuritis, vascular catheter and urinary tract infection, was defined based on the criteria suggested by the US Centers for Disease Control and Prevention.<sup>19</sup> Appropriate antimicrobial therapy was defined as use of a drug to which the isolated pathogen was susceptible in vitro within 48 hours of sampling for culture.<sup>20</sup> Infection was considered to be nosocomially acquired in patients who had been hospitalized for 48 hours or longer. Infection was categorized as early onset if it occurred 2 months (60 days) or less after SOT, or late onset if it occurred >2 months after SOT.<sup>21</sup> MDR *A. baumannii* was defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories, which included aminoglycosides, carbapenems, extended-spectrum cephalosporins, fluoroquinolones, antipseudomonal penicillins +  $\beta$ -lactamase inhibitors, ampicillin–sulbactam, trimethoprim–sulfamethoxazole, tetracyclines, and polymyxins.<sup>22</sup> Septic shock was diagnosed in recipients who had a positive culture and developed persistent dysfunction of at least one organ caused by hypoperfusion that was unresponsive to intravenous fluid challenge and unexplained by other causes.<sup>23</sup> Mortality was regarded as related to infection when death was associated with clinical signs of active *A. baumannii* infection without evidence of any other cause.<sup>24</sup>

### Statistical analysis

Continuous variables are expressed as medians  $\pm$  standard deviation. The  $\chi^2$  and Fisher exact tests were used to analyze categorical variables. Overall in-hospital mortality rates and infection-related 30-day mortality rates were calculated, respectively. Univariate analysis was applied to examine the association between demographic/clinical variables and overall in-hospital/infection-related mortality. We included variables identified ( $P < 0.10$ ) by univariate analyses. Odds ratios (ORs) with 95% confidence interval (CIs) were calculated. Statistical analyses were performed using SPSS for Windows, version 22.0 (IBM Corporation, Armonk, NY, USA). Statistical significance was defined as  $P < 0.05$  (two-tailed).

## Results

During the 12-year study period, 1,502 SOT recipients – 1,305 kidney, 189 liver, three heart, four simultaneous liver–kidney, and one simultaneous kidney–pancreas recipients – in the Third Xiangya Hospital and 319 SOT recipients – 239 kidney, 78 liver, and two simultaneous liver–kidney recipients – in Zhongnan Hospital were enrolled.

A total of 93 episodes of *A. baumannii* infection occurred in 71 SOT recipients: 48 were kidney-transplant recipients (67.6%), 21 liver recipients (29.6%), and two simultaneous liver–kidney recipients (2.8%) (Table 1). The incidence

**Table 1** Demographic, laboratory, and clinical variables of 71 SOT patients with *Acinetobacter baumannii* infection

Characteristics	Value
Age, mean years ± SD	44.5±11.9
Male sex, n (%)	53 (74.6)
Temperature 39°C or greater, n (%)	17 (23.9)
Nosocomial origin, n (%)	64 (90.1)
Inappropriate antimicrobial use, n (%)	41 (57.7)
Induction therapy, n (%)	19 (26.8)
Acute rejection prior to infection, n (%)	13 (18.3)
High-dose steroids for rejection before infection, n (%)	8 (11.3)
Reoperation, n (%)	7 (9.9)
Carbapenem-resistant <i>A. baumannii</i> , n (%)	40 (56.3)
MDR <i>A. baumannii</i> , n (%)	53 (74.6)
ICU stay, n (%)	51 (71.8)
Mechanical ventilation, n (%)	33 (46.5)
Septic shock, n (%)	17 (23.9)
Type of transplantation, n (%)	
Kidney	48 (67.6)
Liver	21 (29.6)
Liver–kidney	2 (2.8)
Site of infection, n (%)	
Bloodstream	23 (32.4)
Lung	20 (28.2)
Intra-abdomen/biliary tract	8 (11.3)
Urinary tract	3 (4.2)
Vascular catheter	1 (1.4)
Multiple culture-positive sites	16 (22.5)
Patient immunosuppressant treatment, n (%)	
Tacrolimus	62 (87.3)
Cyclosporine A	8 (11.3)
Time of infection onset, n (%)	
<2 months posttransplant (early onset)	41 (57.7)
≥2 months posttransplant (late onset)	30 (42.3)
Laboratory variables from blood, n (%)	
Platelet count <50,000/mm <sup>3</sup>	24 (33.8)
Lymphocyte count <300/mm <sup>3</sup>	23 (32.4)
Albumin <30 g/L	12 (16.9)
WBC count >15,000/mm <sup>3</sup>	22 (31.0)
Creatinine >1.5 mg/dL	41 (57.7)
Related mortality, n (%)	29 (40.8)
Overall in-hospital mortality, n (%)	38 (53.5)

**Abbreviations:** SOT, solid-organ transplantation; SD, standard deviation; MDR, multidrug-resistant; ICU, intensive care unit; WBC, white blood cell.

rate of *A. baumannii* infection in SOT recipients was 3.9% (71 of 1,821), with the rate of 3.1% in kidney recipients and 8.4% in liver or simultaneous liver–kidney recipients. High-dose steroids (≥750 mg) were used in eight (11.3%) recipients for acute rejection before *A. baumannii* infection. Tacrolimus and cyclosporine A were used in 62 (87.3%) and eight (11.3%) recipients, respectively. The remaining patient did not use any calcineurin inhibitors between liver transplantation and the onset of *A. baumannii* infection, due to a severe clinical condition. Among these 93 episodes of *A. baumannii* infection, the presumed sources of infection were the bloodstream (n=35, 37.6%), lung (n=33, 35.5%), urinary tract (n=16, 17.2%), intra-abdomen/biliary tract (n=6, 6.5%), thoracic cavity (n=2, 2.2%), and catheter (n=1, 1.1%). The median time to onset of *A. baumannii* infection after SOT transplantation was 38 days (interquartile range 8–111 days), and 61.3% (57 of 93) occurred as early onset.

The mean age for SOT recipients with *A. baumannii* infections was 44.5 years (44.5±11.9 years), among which 53 (74.6%) were male. Ninety percent of recipients had nosocomial origin *A. baumannii* infection. Seventeen patients (23.9%) had a body temperature of 39°C or higher at the onset of *A. baumannii* infection. The most common cases were recipients with *A. baumannii* bacteremias (23 cases, 32.4%), pneumonia (20 cases, 28.2%), and multiple culture-positive site infections (16 cases, 22.5%). Seventy-six percent (71 of 93) of *A. baumannii* were carbapenem-resistant. As far as the number of infected patients with carbapenem-resistant strains was concerned, 40 (56.3%) had carbapenem-resistant strains involved. Fifty-three recipients (74.6%) developed MDR *A. baumannii* infection. Forty-one patients (57.7%) received inappropriate antibiotic treatment. Forty-one patients (57.7%) had *A. baumannii* infection within the first 2 months after SOT. At the onset of *A. baumannii* infection, 71.8% and 46.5% of cases needed ICU stay and mechanical ventilation support, respectively. SOT recipients with late-onset *A. baumannii* infection needed more frequent ICU stays (24 of 30 [80.0%] vs 27 of 41 [65.8%]) and mechanical ventilation support (21 of 30 [70.0%] vs 10 of 41 [24.4%]) than those with early onset infection. Septic shock developed in 23.9% (17 of 71) of all recipients with *A. baumannii* infection and in 37.1% (13 of 35) of all recipients with *A. baumannii* bacteremias. Infection was associated with high overall in-hospital mortality (53.5%) and infection-related 30-day mortality (40.8%). Forty-one, 22, 24, and 23 recipients had a serum creatinine level >1.5 mg/dL, white blood cell count >15,000/mm<sup>3</sup>, platelet count <50,000/mm<sup>3</sup>, and lymphocyte count <300/mm<sup>3</sup>, respectively. The basic demographic, laboratory, and clinical

**Table 2** Risk factors for overall in-hospital mortality in SOT recipients with *Acinetobacter baumannii* infection

Characteristics	Overall mortality	Survival	P-value	OR (95% CI)
Total, n (%)	38 (53.5)	33 (46.5)		
Univariate analysis, n (%)				
Age $\geq 40$ years	27 (71.1)	22 (66.7)	0.690	1.23 (0.45–3.36)
Male sex	26 (68.4)	27 (81.8)	0.200	0.48 (0.16–1.47)
Temperature $\geq 39^\circ\text{C}$	12 (31.6)	5 (15.2)	0.112	2.59 (0.80–8.34)
Inappropriate antibiotics	19 (50.0)	22 (66.7)	0.159	0.50 (0.19–1.31)
Nosocomial infection	35 (92.1)	29 (87.9)	0.554	1.61 (0.33–7.78)
Liver or liver–kidney transplant	17 (44.7)	6 (18.2)	0.020	3.64 (1.22–10.85)
Multiple culture-positive sites	11 (28.9)	5 (15.2)	0.171	2.28 (0.70–7.44)
Late-onset infection	20 (52.6)	10 (30.3)	0.060	2.56 (0.96–6.80)
Acute rejection	6 (15.8)	7 (21.2)	0.557	0.70 (0.21–2.33)
Induction therapy	8 (21.1)	11 (33.3)	0.531	0.71 (0.25–2.05)
Reoperation	5 (13.2)	2 (6.1)	0.328	2.35 (0.42–13.01)
MDR <i>A. baumannii</i>	29 (76.3)	24 (72.7)	0.729	1.21 (0.41–3.53)
ICU stay	35 (92.1)	16 (48.5)	<0.001	12.40 (3.17–48.42)
Mechanical ventilation	27 (71.1)	6 (18.2)	<0.001	11.04 (3.57–34.15)
Septic shock	15 (39.5)	2 (6.1)	0.004	10.11 (2.10–48.63)
Platelet count $< 50,000/\text{mm}^3$	20 (52.6)	4 (12.1)	0.001	8.06 (2.37–27.40)
Lymphocyte count $< 300/\text{mm}^3$	16 (42.1)	7 (21.2)	0.065	2.70 (0.94–7.75)
Albumin $< 30$ g/L	10 (26.3)	2 (6.1)	0.036	5.54 (1.12–27.47)
WBC count $\geq 15,000/\text{mm}^3$	10 (26.3)	12 (36.4)	0.690	0.82 (0.30–2.23)
Creatinine $\geq 1.5$ mg/dL	26 (68.4)	15 (45.5)	0.053	2.60 (0.99–6.85)
Multivariate analysis				
Liver or liver–kidney transplant			0.012	15.33 (1.82–129.18)
Late-onset infection			0.043	7.61 (1.07–54.36)
Mechanical ventilation			0.013	6.29 (1.48–26.85)

**Abbreviations:** SOT, solid-organ transplantation; OR, odds ratio; CI, confidence interval; MDR, multidrug-resistant; ICU, intensive care unit; WBC, white blood cell.

characteristics of all SOT recipients with *A. baumannii* infection are shown in Table 1.

Tables 2 and 3 present the risk factors for overall in-hospital and infection-related mortality, respectively. In univariate analysis, liver or simultaneous liver–kidney transplantation ( $P=0.02$ ), ICU stay ( $P<0.001$ ), mechanical ventilation ( $P<0.001$ ), septic shock ( $P=0.004$ ), albumin level  $< 30$  g/L ( $P=0.036$ ), and platelet count  $< 50,000/\text{mm}^3$  ( $P=0.001$ ) were more likely to develop overall in-hospital mortality. In multivariate logistic regression analysis of these data, mechanical ventilation at onset of *A. baumannii* infection (OR 6.29, 95% CI 1.48–26.85;  $P=0.013$ ), liver or simultaneous liver–kidney transplantation (OR 15.33, 95% CI 1.82–129.18;  $P=0.012$ ), and late-onset *A. baumannii* infection (OR 7.61, 95% CI 1.07–54.36;  $P=0.043$ ) were all associated with a greater risk of overall in-hospital mortality. In univariate analysis, the following variables were significantly associated with infection-related 30-day mortality: temperature  $\geq 39^\circ\text{C}$  ( $P=0.026$ ), late-onset *A. baumannii* infection ( $P=0.022$ ), ICU stay ( $P=0.003$ ), mechanical ventilation ( $P<0.001$ ), septic shock ( $P<0.001$ ), creatinine level  $> 1.5$  mg/dL ( $P=0.041$ ), and platelet count  $< 50,000/\text{mm}^3$  ( $P=0.002$ ). In multivariate

analysis, platelet count  $< 50,000/\text{mm}^3$  (OR 12.76, 95% CI 1.28–126.81;  $P=0.030$ ) and mechanical ventilation at onset of *A. baumannii* infection (OR 189.98, 95% CI 13.23–2,728.81;  $P<0.001$ ) were significantly related to a higher risk of 30-day mortality associated with *A. baumannii* infection.

## Discussion

Invasive bacterial infections have become a leading contributor to patient morbidity and mortality among SOT recipients.<sup>25</sup> *A. baumannii* is an increasing problem among SOT recipients. Not only is *A. baumannii* environmentally resilient but this pathogen can also readily develop antibiotic resistance. van Delden et al reported that the prevalence of MDR *Acinetobacter* is increasing, and is related to higher rates of treatment failure in SOT recipients.<sup>26</sup>

The incidence rate of *A. baumannii* infection in SOT recipients was 3.9% (71 of 1,821), with rates of 3.1% in kidney recipients and 8.4% in liver or simultaneous liver–kidney recipients, in our present study. Although in more transplant centers, including ours, higher-immunosuppression regimens are used in kidney-transplant recipients, the incidence rate of *A. baumannii*

**Table 3** Risk factors for infection-related mortality in SOT recipients with *Acinetobacter baumannii* infection

Characteristics	Related mortality	Survival	P-value	OR (95% CI)
Total, n (%)	29 (40.8)	42 (59.2)		
Univariate analysis, n (%)				
Age $\geq$ 40 years	20 (69.0)	29 (69.0)	0.994	0.99 (0.36–2.77)
Male sex	21 (72.4)	32 (76.2)	0.363	0.61 (0.21–1.78)
Temperature $\geq$ 39°C	11 (37.9)	6 (14.3)	0.026	3.67 (1.17–11.52)
Inappropriate antibiotics	15 (51.7)	26 (61.9)	0.394	0.66 (0.25–1.72)
Nosocomial infection	28 (96.6)	36 (87.9)	0.165	4.67 (0.53–41.03)
Liver or liver–kidney transplant	10 (34.5)	13 (31.0)	0.755	1.17 (0.43–3.21)
Multiple culture-positive sites	9 (31.0)	7 (16.7)	0.160	2.25 (0.73–6.97)
Late-onset infection	17 (58.6)	13 (31.0)	0.022	3.16 (1.18–8.48)
Acute rejection	6 (20.7)	7 (16.7)	0.667	1.30 (0.39–4.38)
Induction therapy	8 (27.6)	11 (26.2)	0.896	1.07 (0.37–3.12)
Reoperation	3 (10.3)	4 (9.5)	0.909	1.10 (0.23–5.31)
MDR <i>A. baumannii</i>	24 (82.8)	29 (69.0)	0.197	2.15 (0.67–6.90)
ICU stay	28 (96.6)	23 (54.8)	0.003	23.13 (2.88–186.10)
Mechanical ventilation	26 (89.7)	7 (16.7)	<0.001	43.33 (10.22–183.73)
Septic shock	14 (48.3)	3 (7.1)	<0.001	12.13 (3.05–48.32)
Platelet count <50,000/mm <sup>3</sup>	16 (55.2)	8 (19.0)	0.002	5.23 (1.81–15.14)
Lymphocyte count <300/mm <sup>3</sup>	13 (44.8)	10 (23.8)	0.066	2.60 (0.94–7.21)
Albumin <30 g/L	8 (27.6)	4 (9.5)	0.055	3.62 (0.97–13.46)
WBC count >15,000/mm <sup>3</sup>	9 (31.0)	13 (31.0)	0.994	1.00 (0.36–2.79)
Creatinine >1.5 mg/dL	21 (72.4)	20 (47.6)	0.041	2.89 (1.05–7.97)
Multivariate analysis				
Mechanical ventilation			<0.001	189.98 (13.23–2,728.81)
Platelet count <50,000/mm <sup>3</sup>			0.030	12.76 (1.28–126.81)

**Abbreviations:** SOT, solid-organ transplantation; OR, odds ratio; CI, confidence interval; MDR, multidrug-resistant; ICU, intensive care unit; WBC, white blood cell.

infection in liver or simultaneous liver–kidney recipients was higher than that in kidney recipients, because patients undergoing liver or simultaneous liver–kidney transplantation had several conditions that favor postoperative *A. baumannii* infection, such as preoperative malnutrition due to end-stage liver disease, insulin resistance, major surgical trauma, massive intraoperative bleeding and transfusions, the placement of various catheters, and long duration of antibiotic use before and after transplantation, which could enhance the likelihood of emergence of *A. baumannii*.

Ninety percent of recipients had *A. baumannii* infection with nosocomial origin in our present study, in alignment with previous studies<sup>5,15</sup> reporting *A. baumannii* to be almost exclusively a nosocomial pathogen. We found that 74.6% of recipients developed MDR *A. baumannii* infection, and the incidence rate of MDR *A. baumannii* was higher than that of MDR *A. baumannii* reported by Kusne et al (64%).<sup>4</sup> The possible reasons to explain this included MDR being defined as resistance to three or more major classes of antibiotics historically effective against *A. baumannii* (fluoroquinolones, carbapenems, aminoglycosides, penicillins, and cephalosporins) in the study conducted by Kusne et al whereas in our present study, MDR was defined as acquired nonsusceptibility to at least one agent

in three or more antimicrobial categories, which included nine classes of antibiotics.

Our present study showed that *A. baumannii* infection was associated with high morbidity (3.9%), as well as high overall in-hospital mortality (53.5%) and infection-related 30-day mortality (40.8%), in line with previous studies that reported an incidence rate of up to 6.1% and an extremely high mortality rate of up to 80% among SOT recipients with *A. baumannii* infection.<sup>5–10</sup>

Mechanical ventilation associated with both overall in-hospital mortality and infection-related 30-day mortality were in agreement with a recent study claiming that the risk of *A. baumannii* infection-associated mortality was higher in SOT patients on mechanical ventilation.<sup>7</sup> Mechanical ventilation support is associated with both overall in-hospital mortality and infection-related 30-day mortality because it probably surrogates markers of clinical severity.<sup>7</sup> We also found that late-onset *A. baumannii* infection was an associated risk factor with overall in-hospital mortality. The association partly reflects the effect of clinical severity on outcomes, given SOT recipients with late-onset *A. baumannii* infection needed more frequent ICU stay (80% vs 66%) and ventilator dependence (70% vs 24%) when compared with recipients with early onset infection.

We revealed that liver or liver–kidney transplantation was significantly related to overall mortality, in accordance with Moreno et al who found liver transplantation to be a risk factor for higher mortality in transplant recipients with bloodstream infections.<sup>27</sup> We also revealed that thrombocytopenia was a risk factor associated with infection-related mortality. This finding probably reflects a confounding factor, as thrombocytopenia developed more frequently among liver recipients who presented with higher baseline clinical severity. Our findings consolidated results from previous studies of SOT recipients, which reported that lower platelet count to be associated with infection-related mortality.<sup>24,28,29</sup>

To the best of our knowledge, this is the largest study specifically focusing on *A. baumannii* infections to investigate the epidemiology, distribution, and risk factors for overall in-hospital and infection-related 30-day mortality in SOT recipients. However, the present study has certain limitations. Firstly, our study was a small retrospective chart review with potential limitations, such as data limited to existing medical records. Secondly, for the relatively small number of cases and deaths, the statistical power may be insufficient. Thirdly, we may have underestimated the true rates of *A. baumannii* infections in SOT recipients, given that 1) cases of *A. baumannii* infections outside our institution were not identified, and 2) some cases received empiric courses of antimicrobial therapy before specimens for bacterial culture were obtained. Finally, though we tried to include all relevant data, other unidentified variables are probably risk factors for mortality. The strength of our study is the long study period covering two centers in two different cities in the PRC. However, given the retrospective data collection and risk for bias, all reported findings should be interpreted with care.

## Conclusion and recommendation

High morbidity and high unfavorable outcomes in SOT recipients with infections due to *A. baumannii* were observed. This study confirmed that the risk factors significantly associated with increased mortality in SOT recipients with *A. baumannii* infection were mechanical ventilation, liver or liver–kidney transplantation, thrombocytopenia, and late-onset infection. Therefore, the clinical and laboratory factors noted in the present study could be useful for clinicians to identify SOT recipients with *A. baumannii* infection who are at high risk for mortality.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Dummer JS, Singh N. Infections in solid organ transplant recipients. In: Mandell GL, Bennett JE, Dolin R. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 7th ed. Philadelphia: Churchill Livingstone; 2010:3839–3850.
- Fishman JA. Infection in solid-organ transplant recipients. *N Engl J Med*. 2007;357:2601–2614.
- Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL. Rates of first infection following kidney transplant in the United States. *Kidney Int*. 2009;75:317–326.
- Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. *Medicine (Baltimore)*. 1988; 67:132–143.
- Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant *Acinetobacter baumannii* infections after organ transplantation. *Transpl Infect Dis*. 2010;12:87–93.
- Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug resistant *Acinetobacter baumannii* infections among solid organ transplant recipients. *PLoS One*. 2012;7:e52349.
- de Gouvêa EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with *Acinetobacter baumannii* infection. *BMC Infect Dis*. 2012; 12:351.
- Kim YJ, Yoon JH, Kim SI, et al. High mortality associated with *Acinetobacter* species infection in liver transplant patients. *Transplant Proc*. 2011;43:2397–2399.
- Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with *Acinetobacter baumannii* infections experienced by lung transplant recipients. *Lung*. 2010;188:381–385.
- Trottier V, Namias N, Pust DG, et al. Outcomes of *Acinetobacter baumannii* infection in critically ill surgical patients. *Surg Infect (Larchmt)*. 2007;8:437–443.
- Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical features and treatment. *Clin Microbiol Infect*. 2002;8:687–693.
- Linares L, Cervera C, Cofán F, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. *Transplant Proc*. 2007;39:2222–2224.
- Falagas ME, Karveli EA. The changing global epidemiology of *Acinetobacter baumannii* infections: a development with major public health implications. *Clin Microbiol Infect*. 2007;13:117–119.
- Morgan DJ, Liang SY, Smith CL, et al. Frequent multidrug-resistant *Acinetobacter baumannii* contamination of gloves, gowns, and hands of healthcare workers. *Infect Control Hosp Epidemiol*. 2010;31: 716–721.
- Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant *Acinetobacter baumannii*. *Emerg Infect Dis*. 2005;11:22–29.
- Monterrubio-Villar J, González-Velasco C, Valdezate-Ramos S, Córdoba-López A, Villalón-Panzano P, Saéz-Nieto JA. Outbreak of multiresistant *Acinetobacter baumannii* in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. *Eur J Clin Microbiol Infect Dis*. 2009;28:1281–1284.
- Munoz-Price LS, Zembower T, Penugonda S, et al. Clinical outcomes of carbapenem-resistant *Acinetobacter baumannii* bloodstream infections: study of a 2-state monoclonal outbreak. *Infect Control Hosp Epidemiol*. 2010;31:1057–1062.
- Kitazono H, Rog D, Grim SA, Clark NM, Reid GE. *Acinetobacter baumannii* infection in solid organ transplant recipients. *Clin Transplant*. 2015;29:227–232.
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control*. 2008;36: 309–332.
- Gao F, Ye QF, Wan QQ, Liu S, Zhou J. The distribution and resistance of pathogens among liver transplant recipients with *Acinetobacter baumannii* infections. *Ther Clin Risk Manag*. 2015;11:501–505.

21. Lee SO, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR. Spectrum of early-onset and late-onset bacteremia after liver transplantation: implications for management. *Liver Transpl.* 2011;17:733–741.
22. Wan Q, Ye Q, Yuan H. Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias. *Eur J Clin Microbiol Infect Dis.* 2015;34:431–437.
23. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. *Crit Care Med.* 2005;33:1845–1853.
24. Wan Q, Ye Q, Zhou J. Mortality predictors of bloodstream infections in solid-organ transplant recipients. *Exp Clin Transplant.* 2013;11:211–214.
25. Kutinova A, Woodward RS, Ricci JF, Brennan DC. The incidence and cost of sepsis and pneumonia before and after renal transplantation in the United States. *Am J Transplant.* 2006;6:129–139.
26. van Delden C, Blumberg EA. Multidrug resistant Gram-negative bacteria in solid organ transplant recipients. *Am J Transplant.* 2009;9 Suppl 4: S27–S34.
27. Moreno A, Cervera C, Gavaldá J, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. *Am J Transplant.* 2007;7:2579–2586.
28. Nieto-Rodriguez JA, Kusne S, Mañez R, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. *Ann Surg.* 1996;223:70–76.
29. Wan Q, Xiao X, Ye Q, Zhou J. [Risk factors for bloodstream infections in liver or kidney transplantation recipients]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.* 2012;37:924–927. Chinese.

## Therapeutics and Clinical Risk Management

### Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

Submit your manuscript here: <http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress